| pubmed-article:8099806 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8099806 | lifeskim:mentions | umls-concept:C0006772 | lld:lifeskim |
| pubmed-article:8099806 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:8099806 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:8099806 | lifeskim:mentions | umls-concept:C0040979 | lld:lifeskim |
| pubmed-article:8099806 | lifeskim:mentions | umls-concept:C0031437 | lld:lifeskim |
| pubmed-article:8099806 | lifeskim:mentions | umls-concept:C0036576 | lld:lifeskim |
| pubmed-article:8099806 | lifeskim:mentions | umls-concept:C0332325 | lld:lifeskim |
| pubmed-article:8099806 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:8099806 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:8099806 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:8099806 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:8099806 | pubmed:dateCreated | 1993-7-21 | lld:pubmed |
| pubmed-article:8099806 | pubmed:abstractText | Trifluoperazine (TFP) is effective in modulating DNA damage/repair in doxorubicin (DOX) treated cells. In the present study we have characterised the resistance phenotype of parental sensitive L1210 mouse leukaemia cells (L1210/S) adapted to grow in the presence of 0.017 microns DOX+5 microM TFP (L1210/DT). Although with prolonged exposure, 0.017 microM DOX alone produced < 35% cell kill in L1210/S cells, similar cytotoxicity was achieved at 0.43 microM DOX in L1210/S cells selected in the presence of 0.017 microM DOX+5 microM TFP. L1210/DT cells were > 30-fold resistant to DOX following a 3 h drug exposure in a soft agar colony assay. In contrast, DOX sensitivity in cells adapted to grow in 5 microM TFP alone was comparable to L1210/S cells. Resistance to other inhibitors of topoisomerase II in L1210/DT cells was > 30-fold to etoposide and > 6-fold to amsacrine. The levels of the 170 kDa and 180 kDa isoforms of topoisomerase II in an immunoblot were comparable between the L1210/S and L1210/DT cells. Cross resistance to vincristine in the L1210/DT cells was accompanied by the overexpression of plasma membrane P-glycoprotein. Although a 1.5-2-fold decrease in accumulation of etoposide and DOX was observed in the L1210/DT cells, drug levels for equivalent DNA damage in the alkaline elution assay were > 5-fold higher in the L1210/DT versus L1210/S cells. No abrogation in the modulating effects of TFP on DOX, VP-16 or amsacrine induced cytotoxicity was apparent in the L1210/DT cells. Results suggest that: (a) TFP in combination with low concentrations DOX can induce the selection of cells with the multidrug resistant phenotype; and (b) characteristics of cells selected for resistance to DOX or DOX plus TFP are comparable. | lld:pubmed |
| pubmed-article:8099806 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8099806 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8099806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8099806 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8099806 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:8099806 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:8099806 | pubmed:author | pubmed-author:FordJJ | lld:pubmed |
| pubmed-article:8099806 | pubmed:author | pubmed-author:GanapathiRR | lld:pubmed |
| pubmed-article:8099806 | pubmed:author | pubmed-author:GrabowskiDD | lld:pubmed |
| pubmed-article:8099806 | pubmed:author | pubmed-author:KamataGG | lld:pubmed |
| pubmed-article:8099806 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8099806 | pubmed:volume | 67 | lld:pubmed |
| pubmed-article:8099806 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8099806 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8099806 | pubmed:pagination | 1203-8 | lld:pubmed |
| pubmed-article:8099806 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:meshHeading | pubmed-meshheading:8099806-... | lld:pubmed |
| pubmed-article:8099806 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8099806 | pubmed:articleTitle | Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype. | lld:pubmed |
| pubmed-article:8099806 | pubmed:affiliation | Department of Cancer Biology, Cleveland Clinic Foundation, Ohio 44195. | lld:pubmed |
| pubmed-article:8099806 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8099806 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
